US10294477 — Compositions and methods for modulating PKK expression
Method of Use · Assigned to Ionis Pharmaceuticals Inc · Expires 2035-05-01 · 9y remaining
What this patent protects
Ionis Pharmaceuticals Inc has patented compositions and methods for decreasing PKK mRNA and protein expression to treat PKK-associated diseases, disorders, and conditions.
USPTO Abstract
Disclosed herein are antisense compounds and methods for decreasing PKK mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate PKK-associated diseases, disorders, and conditions.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-3010 |
— | donidalorsen-sodium |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.